Blockbuster Cancer Drug Can Now Be Administered More Easily

(MedPage Today) — The FDA approved a subcutaneous formulation of the blockbuster cancer drug pembrolizumab (Keytruda Qlex) for use across the drug’s numerous solid tumors indications.
The new formulation combines pembrolizumab with berahyaluronidase…